Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board. The following nuclear medicine physicians and scientists have joined the Company’s advisory board:
|Member||Medical Institution Affiliation|
|David Colcher, Ph.D.||City of Hope|
|Johannes Czernin, M.D.||UCLA|
|Ghassan El-Haddad, M.D.||Moffitt Cancer Center|
|Dan Pryma, M.D.||University of Pennsylvania|
|Franklin Wong, M.D., Ph.D., J.D.||MD Anderson Cancer Center|
|Michael Yu, M.D.||Fox Chase Cancer Center|
Dr. Mark Berger, Actinium’s Chief Medical Officer said, “We are excited to have assembled such a strong advisory board of leading nuclear medicine physicians and scientists. Having access to their input, which is driven by real world experience with our targeted conditioning and ARC drug candidates will be invaluable to our current and future development activities. Based on the excellent contributions from our first meeting, I am confident that the board’s expertise and strategic guidance will position us for future success.”
Actinium is developing Antibody Radio-Conjugates (ARCs) that combine the targeting capabilities of monoclonal antibodies with the cell kill ability of radioisotopes. Actinium’s most advanced ARC, Iomab-B, targets CD45 and is currently being studied in a pivotal Phase 3 trial for targeted conditioning prior to a bone marrow transplant, which is a potentially curative treatment option for patients with a number of hematologic diseases. Actinium is also developing its CD33 program that is being studied in 5 Phase 1 and Phase 2 trial for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma, which all express CD33. Recognizing the importance of the nuclear medicine community to its ARC drug candidates, Actinium has formed Nuclear Medicine Clinical Advisory Board in anticipation of continued clinical development expansion and potential commercialization of Iomab.
Sandesh Seth, Actinium’s Chairman and CEO said, “With Iomab-B progressing in its pivotal Phase 3 trial, our attention is turning to realizing our goal of improving access and outcomes to bone marrow transplant through targeted conditioning. We have formed our nuclear medicine advisory boards to gain insights from physicians at key medical centers that treat a significant number of patients and are expected to be key commercial sites. These advisory boards will augment our also world-class scientific and medical advisory boards that provide expert guidance specific to our Iomab-B and CD33 ARC programs. We are excited to have assembled such esteemed physicians and scientists to our advisory boards and look forward to the contributions they will make to Actinium’s endeavor to be the leader in targeted conditioning.”
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company’s targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.
Iomab-B, Actinium’s lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium’s pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This press release may contain projections or other “forward-looking statements” within the meaning of the “safe-harbor” provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium’s products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the “SEC”), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Actinium Pharmaceuticals, Inc.
Principal Financial Officer
Marek Ciszewski, J.D.
Released July 17, 2018